03/06/23 1:00 AMOTC : RHHBY, CHGCY fda approvalRoche receives FDA approval of label expansion for VENTANA PD-L1 (SP263) Assay to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for LibtayoRoche today announced that the U.S. Food and Drug Administration has approved the VENTANA PD-L1 Assay as a companion diagnostic to identify non-small cell lung cancer patients eligible for treatment with Libtayo ®, a PD-1 inhibitor therapy developed by Regeneron. More than 60 percent of patients diagnosed with NSCLC are diagnosed at locally advanced or...RHEA-AIvery positive
03/02/23 7:00 AMOTC : CHGCY partnershipChugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related PainThe companies have entered a partnership agreement to develop new digital solutions for the objective assessment and management of pain associated with endometriosis, which they have been jointly developing since July 2020 The digital solutions will be rolled out for real-world use with supportRHEA-AIvery positive
02/28/23 1:00 AMOTC : RHHBY, CHGCY Roche joins forces with the U.S. Centers for Disease Control and Prevention to strengthen laboratory systems in the fight against the HIV and tuberculosis epidemicsThrough the implementation of a public-private partnership, named "Lab Networks for Health," Roche and the CDC will seek to improve HIV and tuberculosis prevention, detection, and treatment outcomes in select countries of Africa, Eastern Europe, Central Asia, and the Western Hemisphere. Specifically, Roche and CDC intend to increase laboratory human resource...RHEA-AIneutral
02/09/23 1:00 AMOTC : RHHBY, CHGCY Roche expands collaboration with Janssen to advance personalised healthcare through companion diagnosticsRoche today announced that it has expanded its collaboration with Janssen Biotech Inc. to create companion diagnostics for targeted therapies, further strengthening research and innovation activities. "This is a great example of how Roche is spearheading the next generation of healthcare by working with industry leaders around the globe," said Jill...RHEA-AIvery positive
12/11/22 1:02 AMOTC : RHHBY, CHGCY Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From BirthGenentech, a member of the Roche Group, today announced interim results from the Phase III HAVEN 7 study. The new data were presented at the 64th American Society of Hematology Annual Meeting and Exposition taking place in New Orleans from December 10-13, 2022. The World Federation of Hemophilia treatment guidelines consider the standard of care in...RHEA-AIneutral
11/03/22 9:00 AMOTC : RHHBY, CHGCY conferencesGenentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient NeedsGenentech, a member of the Roche Group, today announced that it will present new data from its industry-leading hematology portfolio at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022. “We continually strive to improve patient outcomes by exploring new treatment options across blood disorders, such as lymphomas and rare...RHEA-AIneutral
07/11/22 5:45 AMOTC : RHHBY, CHGCY New Data From Phase III HAVEN 6 Study Reinforce Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia AGenentech, a member of the Roche Group, today announced results from the primary analysis of the Phase III HAVEN 6 study, which show that Hemlibra ® continued to demonstrate a favorable safety profile and effective bleed control in people with moderate or mild hemophilia A, without factor VIII inhibitors. The data will be presented at the 30th International...RHEA-AIneutral
12/13/21 1:00 AMOTC : RHHBY, CHGCY Interim Data From Phase III HAVEN 6 Study Demonstrate Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia AGenentech, a member of the Roche Group, today announced results from an interim analysis of the Phase III HAVEN 6 study, which show Hemlibra ® demonstrated a favorable safety profile and effective bleed control in people with moderate or mild hemophilia A without factor VIII inhibitors. The data were presented at the 63rd American Society of Hematology...RHEA-AIneutral
11/23/21 9:15 AMOTC : RHHBY, CHGCY conferencesGenentech to Present New Pivotal Data at ASH 2021 From Broad and Comprehensive Portfolio, Challenging Treatment Standards for People With Blood DisordersGenentech, a member of the Roche Group today announced that new data from its extensive hematology portfolio will be presented at the American Society of Hematology Annual Meeting and Exposition from December 11-14, 2021. Genentech molecules will be featured in more than 90 abstracts, including 17 oral presentations, showcasing new immunotherapies,...RHEA-AIneutral
10/14/21 3:30 AMOTC : RHHBY, CHGCY New Four-year Data Show Sustained Relapse Reduction by Chugai’s Enspryng in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)Chugai Pharmaceutical Co., Ltd. announced new longer-term efficacy and safety data for Enspryng ®, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody created by Chugai. Efficacy and safety results from the open-label extension periods of the SAkuraStar and SAkuraSky studies, in addition to the design of SAkuraBONSAI, a new study in...RHEA-AIneutral
